
Centre’s PLI scheme gives booster shot to pharma and medtech sector
New Delhi, Sep 25 (IANS) The Production-Linked Incentive (PLI) schemes have succeeded in strengthening India’s pharmaceutical, bulk drugs and medical devices manufacturing ecosystem, which has helped to reduce import dependence and encouraged technology adoption to build globally competitive capabilities in the pharma and medtech sector, according to a factsheet issued by the government on Friday.The government approved the 'PLI Scheme for Bulk Drugs' in 2020, with a total financial outlay of Rs 6,940 crore. The scheme was launched to strengthen domestic manufacturing of 41 identified critical products and reduce dependence on imports, particularly for APIs and other essential pharmaceutical building blocks.An investment of Rs 5,210.74 crore has been made under the scheme (as on June 2026)...









